Home » Topics » BioWorld Science, Conferences

BioWorld Science, Conferences
RSS

Updated study results on orteronel in prostate cancer presented

Oct. 8, 2012

Empagliflozin has beneficial effects on blood pressure

Oct. 8, 2012

ITCA-650 evaluated in phase II dose-finding study

Oct. 5, 2012

Combination therapy proves useful against head and neck cancer

Oct. 5, 2012

Therapy targeting tumor antigens and immune tolerance evaluated in phase I study

Oct. 5, 2012

Brimonidine improves erythema in patients with rosacea

Oct. 5, 2012

Adalimumab evaluated as a treatment for hidradenitis suppurativa in phase II trial

Oct. 5, 2012

First data on once-weekly DPP IV inhibitor MK-3102 reported

Oct. 4, 2012

Eravacycline compared to ertapenem in patients with intra-abdominal infections

Oct. 4, 2012

Ipragliflozin has beneficial effects in Japanese patients with type 2 diabetes

Oct. 4, 2012

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 9, 2026.
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Hyperexcitability may be joint problem in epilepsy, dementia
BioWorld
The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
FENS 2026: Shedding light on the sheddome
BioWorld
At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...